1.
, , , , . Prognostic impact of BTS (Baseline Tumor Size) on survival outcomes in patients with advanced Non-Small Cell Lung Cancer (NSCLC), treated with Pembrolizumab and Chemotherapy [Internet]. [Nantes]: Nantes Université; 2024. https://archive.bu.univ-nantes.fr/pollux/show/show?id=59a9a10f-33ed-4d8c-82ea-8dc2e4f2258c
, , , et . Prognostic impact of BTS (Baseline Tumor Size) on survival outcomes in patients with advanced Non-Small Cell Lung Cancer (NSCLC), treated with Pembrolizumab and Chemotherapy [en ligne]. Nantes : Nantes Université, 19 mai 2024. Disponible à l’adresse : https://archive.bu.univ-nantes.fr/pollux/show/show?id=59a9a10f-33ed-4d8c-82ea-8dc2e4f2258c
Bellon Thibault, Liberge Renan, Frampas Éric, Blanc François-Xavier, & Pons-Tostivint Elvire. (2022). Prognostic impact of BTS (Baseline Tumor Size) on survival outcomes in patients with advanced Non-Small Cell Lung Cancer (NSCLC), treated with Pembrolizumab and Chemotherapy. Nantes Université.
Style de citation MLA (8e éd.)Bellon Thibault, et al. Prognostic Impact of BTS (Baseline Tumor Size) on Survival Outcomes in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC), Treated with Pembrolizumab and Chemotherapy. Nantes Université, 2022.
Attention : ces citations peuvent ne pas être correctes à 100%.